Enovis Co. (NYSE:ENOV) Shares Sold by Level Four Advisory Services LLC

Level Four Advisory Services LLC lowered its position in shares of Enovis Co. (NYSE:ENOV - Free Report) by 40.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,705 shares of the company's stock after selling 14,825 shares during the period. Level Four Advisory Services LLC's holdings in Enovis were worth $952,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Confluence Investment Management LLC acquired a new stake in Enovis during the fourth quarter worth $3,494,000. Geode Capital Management LLC grew its holdings in shares of Enovis by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 921,437 shares of the company's stock worth $39,678,000 after purchasing an additional 80,165 shares during the period. UMB Bank n.a. increased its position in shares of Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after purchasing an additional 437 shares during the last quarter. Jane Street Group LLC raised its holdings in Enovis by 247.6% in the 3rd quarter. Jane Street Group LLC now owns 106,684 shares of the company's stock valued at $4,593,000 after buying an additional 75,988 shares during the period. Finally, FMR LLC lifted its position in Enovis by 20.5% in the third quarter. FMR LLC now owns 2,840 shares of the company's stock valued at $122,000 after buying an additional 484 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company's stock.

Enovis Trading Down 3.8 %

Shares of NYSE ENOV traded down $1.27 during trading on Friday, reaching $32.52. The stock had a trading volume of 1,488,090 shares, compared to its average volume of 717,915. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The company has a market cap of $1.85 billion, a P/E ratio of -14.85 and a beta of 2.05. Enovis Co. has a fifty-two week low of $31.05 and a fifty-two week high of $62.79. The business's 50-day moving average price is $40.90 and its 200-day moving average price is $43.09.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.06. The company had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. On average, equities research analysts predict that Enovis Co. will post 2.79 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reiterated a "buy" rating and set a $64.00 price target on shares of Enovis in a research report on Wednesday.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.